Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations

| January 29, 2018 | 0 Comments
Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations

The drug olaparib (Lynparza®) is the first treatment approved by the Food and Drug Administration for patients with metastatic breast cancer who have inherited mutations in the BRCA1 or BRCA2 genes.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply